News >

FDA Approves Dabrafenib/Trametinib Combo for BRAF+ Thyroid Cancer

Published: Friday, May 04, 2018

Richard Pazdur, MD

Richard Pazdur, MD
The FDA has approved combination therapy with the BRAF inhibitor dabrafenib (Tafinlar) and the MEK inhibitor trametinib (Mekinist) for the treatment of patients with unresectable or metastatic BRAF V600E–positive anaplastic thyroid cancer.

The confirmed overall response rate (ORR) was 69% (11 of 16; 95% CI, 41-89). One patient had a complete response and 10 had partial responses. Seven patients had ongoing responses at the time of the analysis.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication